刮治法联合重组人干扰素a－2b凝胶治疗扁平疣临床疗效观察  

Observe the clinical effects of verruca planae using the therapeutic method of scaling combined with Recombinant Human Interferon a-2b Gel

作　　者：周郅柯 

机构地区：[1]湖南省岳阳市第二人民医院皮肤科,湖南岳阳414000

出　　处：《中国中医药咨讯》2011年第8期192-193,共2页

摘　　要：目的：观察刮治法联合重组人干扰素a－2b凝胶（尤靖安）治疗扁平疣的临床疗效。方法：将56例患者随机分为治疗组和对照组，各28例，治疗组采用刮治法联合重组人干扰素a－2b凝胶（尤靖安）治疗扁平疣，对照组采用重组人干扰素a-2b凝胶外用。每周观察两组皮损的变化情况，于治疗8周后评价疗效。结果：8周后进行疗效观察，治疗组28例，临床痊愈19例（67．86％），显效4例（14．29％），有效3例（10.71％），无效2例（7．14％），总有效率为92．86％；对照组28例临床痊愈6例（21．43％），显效3例（10．71％），有效4例（14．29％），无效15例（53．57％），总有效率为46．42％；两组总疗效就有显著性差异（P〈0．05）。结论：刮治法联合重组人干扰素a-2b凝胶f尤靖安）治疗扁平疣具有较好疗效，[ Abstract ] Objective To observe the clinical effects of verruca planae using the therapeutic method of scaling combined with Recombinant Human Interferon a-2b Gel .Methods 56 patients with verruca planae were divided into two groups randomly,treatment group and controlled group, they were both 28 cases and used externally Recombinant Human Interferon a-2b Gel .The treatment one added to the treatment of scaling. The leision changes of the two groups were observed weekly, while curative effects were assessed after 8 weeks therapy. Results 28 patients of the treatment group completed the 8-week trial,including 19 cases （67.86%） were cured,4 （14.29%） remarkably effective,3 （10.71%） effective,2 （7.14%） ineffective,the total effective rate was 92.86 percent.While in the control group,6 cases （21.43%） were cured,3 （10.71%） remarkably effective,4 （14.29%） effective, 15 （53.57%） ineffective, the total effective rate was 46.42 percent.The difference of effective rate between two groups were statistically significant （P〈0.05）.Conclusions using the therapeutic method of scaling combined with Recombinant Human Interferon a-2b Gel had the more prominent benefit in patients with verruca planae.

关 键 词：扁平疣 刮治法 临床疗效 

分 类 号：R512.62[医药卫生—内科学]